Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid by D'Haens, G, Reinisch, W, Panaccione, R, Satsangi, J, Petersson, J, Petersson, J, Arikan, D, Perotti, E, Robinson, A, Kalabic, J, Alperovich, G, Thakkar, R, Loftus, E